Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 8

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 8
---
 systems to solicit participation in the pivotal
trial, which resulted in a positive response from 22 VA medical centers. Academic, private, military, and VA centers currently are being
qualified as collection sites for the 3,200-patient clinical trial expected to open in the second quarter of 2025.

Case Studies

In March 2025, we announced the release of physicians’
case studies showing the benefit to patients and their doctors of using CyPathLung, including one case in which an “Unlikely
Lung Cancer” directly prevented a robotic bronchoscopic biopsy or high-risk percutaneous biopsy in a high-risk patient in response
to imaging that showed several new, small non-calcified pulmonary nodules for a high-risk patient. In a second case study, a positive
CyPath Lung test result led to diagnosis of a recurrence of breast cancer, and a third case resulted in the diagnosis
of a new primary lung cancer after a CyPath Lung positive test that prompted a biopsy that otherwise would not have been
performed.

Targeted Strategic Actions

In March 2025, we announced targeted strategic actions
to improve financial performance and accelerate the commercial growth of CyPath Lung, taking steps to deliver approximately
$4 million in annual cost savings at our subsidiary PPLS, while increasing resources to expand CyPath Lung sales in high-potential
national markets. Specifically, cost savings are a result of labor cost reductions, operational efficiency enhancements, and discontinuing
certain pathology services with suboptimal profit margins to focus on high-margin services such as CyPath Lung and by
discontinuing certain pathology services with suboptimal profit margins.

| 1 |

Continuation of Department of Defense Research

Beginning in the fourth quarter of 2023 and through
2024, we have been selling CyPath Lung tests to the Department of Defense (DOD) to conduct an observational study, “Detection
of Abnormal Respiratory Cell Populations in Lung Cancer Screening Patients Using the CyPath Lung Assay,” and for
research and development on using bronchoalveolar lavage fluid as a biological sample to assess cardiopulmonary function and exercise
performance in military personnel post COVID-19 infection.

Corporate Information

We were incorporated in the State of Delaware on March
26, 2014. Our principal executive office is located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217, and our telephone number
at that address is